Preliminary study on proteomics of gastric carcinoma and its clinical significance

World Journal of Gastroenterology

Volumn 11, Issue 40, 2005, Pages 6249-6253

  Qian, Hong Gang ^a   Shen, Jing ^a   Ma, Hong ^a   Ma, Hua Chong ^b   Su, Ya Hui ^a   Hao, Chun Yi ^a   Xing, Bao Cai ^a   Huang, Xin Fu ^a   Shou, Cheng Chao ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Gastric cancer; SELDI TOF MS; Serum

Indexed keywords

BIOLOGICAL MARKER; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOLOGICAL MODEL; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER STAGING; CHINA; COMPUTER PROGRAM; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; STOMACH CARCINOMA; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

EID: 29544431571     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i40.6249     Document Type: Article

References (32)

1. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999; 83: 18-29
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-1504
3. Gaspar MJ, Arribas I, Coca MC, Diez-Alonso M. Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. Tumour Biol 2001; 22: 318-322
4. Marrelli D, Roviello F, De Stefano A, Farnetani M, Garosi L, Messano A, Pinto E. Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma. Oncology 1999; 57: 55-62
5. Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H, Haglund C. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res 2002; 22: 2311-2316
6. Takahashi Y, Takeuchi T, Sakamoto J, Touge T, Mai M, Ohkura H, Kodaira S, Okajima K, Nakazato H; Tumor Marker Committee. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer 2003; 6: 142-145
7. Issaq HJ, Conrads TP, Prieto DA, Tirumalai R, Veenstra TD. SELDI-TOF MS for diagnostic proteomics. Anal Chem 2003; 75: 148-155
8. Wiesner A. Detection of tumor markers with ProteinChip technology. Curr Pharm Biotechnol 2004; 5: 45-67
9. Tang N, Tornatore P, Weinberger SR. Current developments in SELDI affinity technology. Mass Spectrom Rev 2004; 23: 34-44
10. Shiwa M, Nishimura Y, Wakatabe R, Fukawa A, Arikuni H, Ota H, Kato Y, Yamori T. Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform. Biochem Biophys Res Commun 2003; 309: 18-25
11. Caputo E, Moharram R, Martin BM. Methods for on-chip protein analysis. Anal Biochem 2003; 321: 116-124
12. Weinberger SF, Dalmasso EA, Fung ET. Current achievements using ProteinChip Array technology. Curr Opin Chem Biol 2002; 6: 86-91
13. Fung ET, Thulasiraman V, Weinberger SR, Dalmasso EA. Protein biochips for differential profiling. Curr Opin Biotechnol 2001; 12: 65-69
14. Issaq HJ, Veenstra TD, Conrads TP, Felschow D. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 2002; 292: 587-592
15. Kozak KR, Amneus MW, Pusey SM, Su F, Luong MN, Luong SA, Reddy ST, Farias-Eisner R. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci USA 2003; 100: 12343-12348
16. Petricoin EF, Liotta LA. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol 2004; 15: 24-30
17. Cazares LH, Adam BL, Ward MD, Nasim S, Schellhammer PF, Semmes OJ, Wright GL Jr. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin Cancer Res 2002; 8: 2541-2552
18. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002; 48: 1296-1304
19. Coombes KR, Fritsche HA Jr, Clarke C, Chen JN, Baggerly KA, Morris JS, Xiao LC, Hung MC, Kuerer HM. Quality control and peak finding for proteomics data collected from nipple aspirate fluid by surface-enhanced laser desorption and ionization. Clin Chem 2003; 49: 1615-1623
20. Schaub S, Wilkins J, Weiler T, Sangster K, Rush D, Nickerson P. Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int 2004; 65: 323-332
21. Sasaki K, Sato K, Akiyama Y, Yanagihara K, Oka M, Yamaguchi K. Peptidomics-based approach reveals the secretion of the 29-residue COOH-terminal fragment of the putative tumor suppressor protein DMBT1 from pancreatic adenocarcinoma cell lines. Cancer Res 2002; 62: 4894-4898
22. Cho WC, Yip TT, Yip C, Yip V, Thulasiraman V, Ngan RK, Yip TT, Lau WH, Au JS, Law SC, Cheng WW, Ma VW, Lim CK. Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 2004; 10: 43-52
23. Espina V, Dettloff KA, Cowherd S, Petricoin EF 3rd, Liotta LA. Use of proteomic analysis to monitor responses to biological therapies. Expert Opin Biol Ther 2004; 4: 83-93
24. Srinivas PR, Kramer BS, Srivastava S. Trends in biomarker research for cancer detection. Lancet Oncol 2001; 2: 698-704
25. Chambers G, Lawrie L, Cash P, Murray GI. Proteomics: a new approach to the study of disease. J Pathol 2000; 192: 280-288
26. Hobbs SK, Shi G, Homer R, Harsh G, Atlas SW, Bednarski MD. Magnetic resonance image-guided proteomics of human glioblastoma multiforme. J Magn Reson Imaging 2003; 18: 530-536
27. Sauter ER, Zhu W, Fan XJ, Wassell RP, Chervoneva I, Du Bois GC. Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer. Br J Cancer 2002; 86: 1440-1443
28. Zhukov TA, Johanson RA, Cantor AB, Clark RA, Tockman MS. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. Lung Cancer 2003; 40: 267-279
29. Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath S, Canto MI, Yeo CJ, Chan DW, Goggins M. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004; 10: 860-868
30. Bandera CA, Ye B, Mok SC. New technologies for the identification of markers for early detection of ovarian cancer. Curr Opin Obstet Gynecol 2003; 15: 51-55
31. Rogers MA, Clarke P, Noble J, Munro NP, Paul A, Selby PJ, Banks RE. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res 2003; 63: 6971-6983
32. Fels LM, Buschmann T, Meuer J, Reymond MA, Lamer S, Rocken C, Ebert MP. Proteome analysis for the identification of tumor-associated biomarkers in gastrointestinal cancer. Dig Dis 2003; 21: 292-298